Edwards Lifesciences has obtained European regulatory approval for its SAPIEN M3 system, making it the world’s first transcatheter mitral valve replacement therapy delivered via a transfemoral approach for treating mitral regurgitation.
Phase II trial demonstrates superior outcomes compared to synthetic grafts in both civilian and military settings, with significantly lower amputation rates and infection risks.
A European research initiative has made significant progress in identifying new treatments to protect heart muscle during acute cardiac events, with potential implications for both diabetic and non-diabetic patients.
In an historic achievement, Dr. Feras Khaliel and his team at King Faisal Specialist Hospital & Research Centre (KFSHRC) in Riyadh, Saudi Arabia, successfully performed the world’s first fully robotic heart transplant on a 16-year-old patient with end-stage heart failure. This innovative procedure reduced recovery times and surgical risks, setting a new standard for cardiac […]
A study from Karolinska Institutet reveals that low levels of anti-phosphorylcholine antibodies may indicate increased risk of heart disease in older women, potentially paving the way for improved risk assessment and preventive strategies.
The American Heart Association and American College of Cardiology have jointly published an updated guideline for managing cardiovascular risks in patients undergoing noncardiac surgery, reflecting a decade of new evidence since the last update in 2014.
New research reveals that patients with stable coronary artery disease who quit smoking at any point after diagnosis can reduce their risk of major cardiovascular events by nearly 50%. The study, presented at ESC Congress 2024, also found that merely reducing smoking habits had minimal impact on cardiovascular risk.
A series of groundbreaking studies from Poland have shed new light on the prevalence and impact of lipoprotein(a) [Lp(a)] on cardiovascular health, prompting calls for routine measurement of this important biomarker.
A groundbreaking titanium artificial heart with a single moving part has been successfully implanted in a patient with end-stage heart failure, potentially revolutionising treatment options for those awaiting transplantation.
Royal Philips has announced the successful first implantation of its Duo Venous Stent System following premarket approval from the U.S. Food and Drug Administration. The device is indicated for treating symptomatic venous outflow obstruction in patients with chronic venous insufficiency (CVI).
April 2024
Beukenlaan 137
5616 VD Eindhoven
The Netherlands
+31 85064 55 82
info@interhospi.com
PanGlobal Media IS not responsible for any error or omission that might occur in the electronic display of product or company data.
BiVACOR